Extended Data Table 4 Surgical delay summaries

From: Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial

  1. Data cutoff: December 19, 2024.
  2. A surgical delay is defined as surgery occurring >40 days after the last dose of investigational product in the neoadjuvant period.
  3. Denominator is number of patients who received at least one administration of neoadjuvant treatment and surgery.
  4. *All surgical delays reported as Other were confirmed to be due to logistical, patient preference, or other scheduling issues.
  5. CT, platinum-doublet chemotherapy; Dato-DXd, datopotamab deruxtecan; mona, monalizumab; ole, oleclumab; Plt, single agent platinum chemotherapy; TEAE, treatment-emergent adverse event.
Back to article page